论文部分内容阅读
给予83例特发性蛛网膜下腔出血(SAH)患者口服、鼻饲或静注6-氨基己酸(EACA)36g/日,分6次给药,82例 SAH 患者未给予抗纤维蛋白溶解剂作为对照。结果 EACA 治疗组中3例(4%)有复发性出血,其中1例死亡,而对照组中22例(27%)有复发性出血,其中10例死亡。EACA 最常见的副作用是恶心,呕吐和腹泻,未见血液学障碍。EACA 的主要作用是竞争性地抑制把无活性的纤维蛋白溶酶原转化为有活性的激活剂,它尚有抑制纤维蛋白溶酶的作用,并可降低血液纤维蛋白溶酶原
Eighty-three patients with idiopathic subarachnoid hemorrhage (SAH) were given oral, nasal or intravenous 6-aminocaproic acid (EACA) 36 g daily for 6 administrations and 82 patients with SAH were given no anti-fibrinolytic agents as comparison. Results Of 3 (4%) patients with recurrent hemorrhage in the EACA-treated group, 1 died and 22 (27%) had recurrent hemorrhage in the control group, 10 of whom died. The most common side effects of EACA are nausea, vomiting and diarrhea with no haematological disorders. The main role of EACA is to competitively inhibit the conversion of inactive plasminogen to an active activator, which also inhibits the action of plasmin and reduces blood plasminogen